CLINICAL TRIALS PROFILE FOR JUNIOR STRENGTH ADVIL

All Clinical Trials for Junior Strength Advil

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00435500 ↗	Fluoride Varnish in the Prevention of Dental Caries in Aboriginal and Non-aboriginal Children	Unknown status	Canadian Institutes of Health Research (CIHR)	Phase 3	2003-06-01	The purpose of this study is to determine whether semi-annual fluoride varnish applications combined with caregiver counseling are effective in preventing and reducing a severe form of dental decay, known as early childhood caries, in native and non-native children aged 6 months to 5 years.
NCT00435500 ↗	Fluoride Varnish in the Prevention of Dental Caries in Aboriginal and Non-aboriginal Children	Unknown status	The Hospital for Sick Children	Phase 3	2003-06-01	The purpose of this study is to determine whether semi-annual fluoride varnish applications combined with caregiver counseling are effective in preventing and reducing a severe form of dental decay, known as early childhood caries, in native and non-native children aged 6 months to 5 years.
NCT00435500 ↗	Fluoride Varnish in the Prevention of Dental Caries in Aboriginal and Non-aboriginal Children	Unknown status	University of Toronto	Phase 3	2003-06-01	The purpose of this study is to determine whether semi-annual fluoride varnish applications combined with caregiver counseling are effective in preventing and reducing a severe form of dental decay, known as early childhood caries, in native and non-native children aged 6 months to 5 years.
NCT00931398 ↗	Treatment of College Students With Attention-Deficit/Hyperactivity Disorder (ADHD) Using OROS Methylphenidate	Withdrawn	Ortho-McNeil Janssen Scientific Affairs, LLC	Phase 4	2010-04-01	The purpose of the proposed study is to determine the effectiveness of methylphenidate HCl (Concerta) in college students with ADHD. This study will consist of 110 college students between the ages of 18 and 25 who are enrolled full-time in a local or junior college. The study consists of an 8-week double-blind, placebo-controlled trial of placebo versus methylphenidate HCl (Concerta®) followed by a 10-week extension of open label methylphenidate HCl (Concerta®).
NCT00931398 ↗	Treatment of College Students With Attention-Deficit/Hyperactivity Disorder (ADHD) Using OROS Methylphenidate	Withdrawn	University of Pittsburgh	Phase 4	2010-04-01	The purpose of the proposed study is to determine the effectiveness of methylphenidate HCl (Concerta) in college students with ADHD. This study will consist of 110 college students between the ages of 18 and 25 who are enrolled full-time in a local or junior college. The study consists of an 8-week double-blind, placebo-controlled trial of placebo versus methylphenidate HCl (Concerta®) followed by a 10-week extension of open label methylphenidate HCl (Concerta®).
NCT01566409 ↗	Maintenance Treatment for Children With Constipation	Completed	Kolding Sygehus	N/A	2013-09-01	Constipation is a common problem among children. The majority of children suffering from constipation have no underlying disease. Although constipation has no basis in underlying disease, it often leads to a reduced quality of life of children who are on par with or worse than for children suffering from serious diseases such as cardiovascular and rheumatic diseases. Despite the high frequency of constipation among children, little is known about the causes and treatment of constipation. Treatment consists of symptomatic treatment with various laxatives. Movicol and Movicol junior has proven very effective and are therefore widely used in children as disimpaction and maintenance treatment. There is currently no research to prove the need for and length of maintenance treatment with laxative medications in children. The purpose is to examining the effectiveness of maintenance treatment with Movicol. Additional til study will examine how the anal diameter change during a course of treatment and the degree to which it can be used as an indicator of treatment efficacy. The study will test the following: • What is the effect of maintenance treatment with PEG compared to placebo? The results from this study are expected to form the basis for an evidence-based approach to the use of maintenance therapy and the use of ultrasound of the rectum in children with constipation.
NCT01566409 ↗	Maintenance Treatment for Children With Constipation	Completed	University of Southern Denmark	N/A	2013-09-01	Constipation is a common problem among children. The majority of children suffering from constipation have no underlying disease. Although constipation has no basis in underlying disease, it often leads to a reduced quality of life of children who are on par with or worse than for children suffering from serious diseases such as cardiovascular and rheumatic diseases. Despite the high frequency of constipation among children, little is known about the causes and treatment of constipation. Treatment consists of symptomatic treatment with various laxatives. Movicol and Movicol junior has proven very effective and are therefore widely used in children as disimpaction and maintenance treatment. There is currently no research to prove the need for and length of maintenance treatment with laxative medications in children. The purpose is to examining the effectiveness of maintenance treatment with Movicol. Additional til study will examine how the anal diameter change during a course of treatment and the degree to which it can be used as an indicator of treatment efficacy. The study will test the following: • What is the effect of maintenance treatment with PEG compared to placebo? The results from this study are expected to form the basis for an evidence-based approach to the use of maintenance therapy and the use of ultrasound of the rectum in children with constipation.

Clinical Trial Conditions for Junior Strength Advil

Condition Name

Condition Name for Junior Strength Advil
Intervention	Trials
Constipation	3
Venous Thromboembolism	2
House Dust Mite Allergy	1
Agitated; State, Acute Reaction to Stress	1

Condition MeSH

Condition MeSH for Junior Strength Advil
Intervention	Trials
Constipation	3
Venous Thromboembolism	2
Thromboembolism	2
Hypotension	2

Clinical Trial Locations for Junior Strength Advil

Trials by Country

Trials by Country for Junior Strength Advil
Location	Trials
United States	33
Germany	12
Austria	8
United Kingdom	8
Australia	7

Trials by US State

Trials by US State for Junior Strength Advil
Location	Trials
Pennsylvania	4
Illinois	3
Georgia	3
Texas	2
Ohio	2

Clinical Trial Progress for Junior Strength Advil

Clinical Trial Phase

Clinical Trial Phase for Junior Strength Advil
Clinical Trial Phase	Trials
Phase 4	12
Phase 3	3
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for Junior Strength Advil
Clinical Trial Phase	Trials
Completed	13
Unknown status	5
Recruiting	4

Clinical Trial Sponsors for Junior Strength Advil

Sponsor Name

Sponsor Name for Junior Strength Advil
Sponsor	Trials
Ain Shams University	4
Bayer	3
Bioforce AG	2

Sponsor Type

Sponsor Type for Junior Strength Advil
Sponsor	Trials
Other	44
Industry	15
U.S. Fed	1

Junior Strength Advil: Clinical Trials, Market Analysis, and Projections

Introduction

Junior Strength Advil, containing the active ingredient ibuprofen, is a widely used over-the-counter (OTC) medication for relieving pain and reducing fever in children. This article delves into the clinical trials, market analysis, and future projections for Junior Strength Advil.

Clinical Trials and Safety

Efficacy and Safety Studies

Numerous clinical trials have been conducted to assess the efficacy and safety of ibuprofen in children. Studies have shown that ibuprofen is well-tolerated in children at doses of 20–30 mg/kg, with over 100,000 children enrolled in these trials[5].

A comprehensive review of studies comparing acetaminophen and ibuprofen in children found no clear evidence that the two drugs differ significantly in terms of safety. The risk ratios for minor and major harm were close to 1.00, indicating no significant difference between the two medications[1].

Pediatric Population Focus

There is a growing need for clinical trials that focus on the pediatric population, especially children younger than 2 years and infants younger than 6 months, who have been understudied in previous research[1].

FDA Approvals

The U.S. Food and Drug Administration (FDA) has approved intravenous (IV) ibuprofen for pediatric use, which has boosted the demand for IV ibuprofen injections. This approval highlights the ongoing efforts to ensure the safety and efficacy of ibuprofen in children[3].

Market Analysis

Market Size and Growth

The Advil market, which includes Junior Strength Advil, was valued at $21.01 billion in 2023 and is projected to reach $31.03 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 5.1% during the forecast period[2].

End-User Segmentation

The market for Junior Strength Advil is segmented primarily by end-users, with adults and children being the main categories. While adults dominate the market due to their higher prevalence of chronic conditions like arthritis and menstrual cramps, the pediatric segment is expected to witness considerable growth due to an increasing pediatric population[2].

Regional Market Trends

The Advil market, including Junior Strength Advil, shows varied growth trends across different regions. Europe, particularly countries like Germany, France, and the UK, has a high demand due to a strong healthcare system and a high propensity for self-medication. The Asia-Pacific region, especially China, is expected to register significant growth due to increasing healthcare spending and a large pediatric population[2].

Competitive Landscape

The market for Junior Strength Advil faces competition from other OTC pain relievers, including acetaminophen and natural or herbal alternatives. The presence of generics and other branded medications also poses a challenge, as consumers are increasingly price-sensitive and seek cost-effective solutions[2].

Market Drivers

Increasing Awareness of Pain Management

Public health campaigns, educational programs, and advice from medical professionals have raised consumer awareness about effective pain management techniques. This increased awareness drives the demand for reliable OTC pain relievers like Junior Strength Advil[2].

Growing Chronic Illness Rates

The rising prevalence of chronic illnesses such as arthritis, headaches, and muscular soreness among both adults and children contributes to the growing demand for pain relief medications like Junior Strength Advil[2].

Market Constraints

Competition from Alternatives

The market for Junior Strength Advil is constrained by the growing popularity of natural and herbal medicines, as well as generics and other branded medications that offer comparable effectiveness at lower prices[2].

Price Sensitivity

Consumers' increasing price sensitivity due to rising healthcare and living costs affects the sales of Junior Strength Advil. Companies must innovate and adjust pricing strategies to maintain market share[2].

Future Projections

Growth in Pediatric Segment

The pediatric segment is expected to see significant growth due to the increasing pediatric population and the FDA's approval of IV ibuprofen for pediatric use. This trend is likely to continue as more research focuses on the specific needs of children[3].

Regional Expansion

The market for Junior Strength Advil is expected to expand in regions like the Asia-Pacific, Latin America, and the Middle East and Africa, driven by increasing healthcare spending, urbanization, and changing consumer habits[2].

Innovation and Development

Companies are expected to innovate in formulations and delivery methods, such as intravenous ibuprofen, to stay competitive. For instance, developments like Cumberland Pharmaceuticals' FDA-approved caldolor (intravenous ibuprofen) are anticipated to contribute to market growth[3].

Key Takeaways

• Clinical Trials: Ibuprofen has been extensively studied in children, with over 100,000 participants in clinical trials, demonstrating its safety and efficacy.
• Market Growth: The Advil market, including Junior Strength Advil, is projected to grow at a CAGR of 5.1% from 2023 to 2031.
• End-User Segmentation: The market is segmented into adults and children, with the pediatric segment expected to see significant growth.
• Regional Trends: Europe and the Asia-Pacific region are key markets, with growing demand driven by healthcare spending and population growth.
• Competitive Landscape: The market faces competition from alternatives, generics, and other branded medications, necessitating innovative strategies and competitive pricing.

FAQs

What is the projected market size for Advil by 2031?

The Advil market is projected to reach $31.03 billion by 2031, growing at a CAGR of 5.1% from 2023 to 2031[2].

How safe is ibuprofen for children?

Ibuprofen is well-tolerated in children at doses of 20–30 mg/kg, with extensive clinical trials supporting its safety and efficacy in the pediatric population[5].

What are the main drivers of the Advil market?

The main drivers include increasing awareness of pain management, growing chronic illness rates, and expanding healthcare spending in various regions[2].

What challenges does the Advil market face?

The market faces challenges from competition by natural and herbal alternatives, generics, and other branded medications, as well as consumer price sensitivity[2].

Are there any recent FDA approvals that impact the market for Junior Strength Advil?

Yes, the FDA has approved intravenous (IV) ibuprofen for pediatric use, which is expected to boost the demand for ibuprofen-based products like Junior Strength Advil[3].

Sources

1. Efficacy and Safety of Acetaminophen vs Ibuprofen for Treating Children's Pain or Fever - JAMA Pediatrics.
2. Advil Market Size, Share, Trends, Opportunities And Forecast - Verified Market Research.
3. Intravenous (IV) Ibuprofen Market Size | Growth Prediction 2030 - Allied Market Research.
4. Pediatric Clinical Trials Market Size to Hit USD 27.65 Billion by 2033 - BioSpace.
5. Junior Strength Advil Tablets - Haleon Health Partner.

Last updated: 2025-01-06